This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human HSP90AA1 / HSP86 Protein, GST Tag
catalog :
HS1-H513x
quantity :
100 ug, 1 mg
price :
250 USD, 1600 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
HS1-H513x
product name :
Human HSP90AA1 / HSP86 Protein, GST Tag
quantity :
100 ug, 1 mg
price :
250 USD, 1600 USD
quantity & price :
$250/100ug,$1600/1mg
target :
HSP90AA1
host species :
Human
By Tag :
GST Tag
Research :
For Research Use Only
Source :
Human HSP90AA1, GST Tag (HS1-H513x) is expressed from E.coli cells. It contains AA Glu 535 - Asp 732 (Accession # NP_005339).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>85% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human HSP90AA1, GST Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 85%.
Formulation :
Lyophilized from 0.22 μm filtered solution in 50 mM HEPES, 150 mM NaCl, pH7.0. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Heat shock protein HSP 90-alpha (HSP90AA1 or HSP90A) is also known as Heat shock 86 kDa (HSP 86 or HSP86), Renal carcinoma antigen NY-REN-38, HSPC1, HSPCA, EL52, HSP89A, HSP90N, HSPCAL1, HSPCAL4, HSPN, Hsp89, Hsp90, LAP2, which belongs to the heat shock protein 90 family. HSP90AA1 undergoes a functional cycle that is linked to its ATPase activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. HSP90AA1 interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function.
References :
(1) Martinez-Ruiz A., et al., 2005, Proc. Natl. Acad. Sci. U.S.A. 102:8525-8530.
(2) Forsythe H.L., et al., 2001, J. Biol. Chem. 276:15571-15574.
(3) Yang J., et al., 2005, EMBO J. 24:1-10.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments